Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM4 | P08173 | 1/20 | 0.56 |
| ▸ | DRD2 | P14416 | 1/20 | 0.54 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.53 |
| ▸ | USP5 | P45974 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 2/20 | 0.47 |
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | STAT1 | P42224 | 1/20 | 0.47 |
| ▸ | CCR2 | P41597 | 4/20 | 0.46 |
| ▸ | HTR2C | P28335 | 2/20 | 0.46 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.46 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.46 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29710209 | 1.00 | CHRM4 (0.56) | CHRM4DRD2HCRTR2USP5NPC1 | |
| SCHEMBL6780159 | 0.78 | GRIN2B (0.47) | CHRM4DRD2HCRTR2USP5CCR2 | |
| SCHEMBL21959006 | 0.78 | TEAD1 (0.61) | CHRM4DRD2NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL7552865 | 0.77 | GRIN2B (0.47) | CHRM4DRD2HCRTR2USP5CCR2 | |
| SCHEMBL6896252 | 0.77 | GRIN2B (0.47) | CHRM4DRD2HCRTR2USP5CCR2 | |
| SCHEMBL6896250 | 0.77 | GRIN2B (0.47) | CHRM4DRD2HCRTR2USP5CCR2 | |
| SCHEMBL12524340 | 0.76 | DRD2 (0.73) | DRD2HTR2C | |
| SCHEMBL1581482 | 0.76 | DRD2 (0.58) | CHRM4DRD2USP5CCR2HTR2C | |
| SCHEMBL1761033 | 0.75 | DRD2 (0.56) | CHRM4DRD2USP5CCR2HTR2C | |
| Oxalic Acid SCHEMBL11408676 | 0.75 | DRD2 (0.67) | DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12616695-B2 | Use of 5-amino-2,3-dihydro-1,4-phthalazinedione in the treatment of rare chronic inflammatory pulmonary diseases | METRIOPHARM AG (CH) | 2026-05-05 | — | — | US | disclosed |
| US-20250051288-A1 | METHOD FOR SOLUBILIZING 5-AMINO-2,3-DIHYDRO-1,4-PHTHALAZINEDIONE | METRIOPHARM AG (CH) | 2025-02-13 | — | — | US | disclosed |
| EP-4178579-B1 | 5-AMINO-2,3-DIHYDRO-1,4-PHTHALAZINEDIONE AS GLUCOCORTICOID-SPARING AGENT | METRIOPHARM AG (CH) | 2025-02-12 | — | — | EP | disclosed |
| US-12122753-B2 | Method for solubilizing 5-amino-2,3-dihydro-1,4-phthalazinedione | METRIOPHARM AG (CH) | 2024-10-22 | — | — | US | disclosed |
| CN-111587243-B | Method for solubilising 5-amino-2, 3-dihydro-1, 4-phthalazinediones | 麦翠奥制药公司 | 2024-04-12 | — | — | CN | disclosed |
| US-20230241060-A1 | GLUCOCORTICOID-SPARING AGENT | METRIOPHARM AG (CH) | 2023-08-03 | — | — | US | disclosed |
| EP-3737668-B1 | METHOD FOR SOLUBILIZING 5-AMINO-2,3-DIHYDRO-1,4-PHTHALAZINEDIONE | METRIOPHARM AG (CH) | 2023-06-07 | — | — | EP | disclosed |
| CN-115916258-A | Glucocorticoid reducing agent | 麦翠奥制药公司 | 2023-04-04 | — | — | CN | disclosed |
| US-20230053455-A1 | USE OF 5-AMINO-2,3-DIHYDRO-1,4-PHTHALAZINEDIONE IN THE TREATMENT OF RARE CHRONIC INFLAMMATORY PULMONARY DISEASES | METRIOPHARM AG (CH) | 2023-02-23 | — | — | US | disclosed |
| CN-115536594-A | 5-amino-2,3-dihydrothiazine-1,4-dione crystal | 麦翠奥制药公司 | 2022-12-30 | — | — | CN | disclosed |
| EP-3416951-A1 | CRYSTALLINE FORM OF 5-AMINO-2,3-DIHYDROPHTHALAZINE-1,4-DIONE | MetrioPharm AG (CH) | 2018-12-26 | — | — | EP | disclosed |
| US-20170368063-A1 | CRYSTALLINE FORM OF 5-AMINO-2,3-DIHYDROPHTHALAZINE-1,4-DIONE SODIUM SALT, PHARMACEUTICAL PREPARATIONS CONTAINING THE SAME AND METHOD FOR THE PRODUCTION OF SAID FORM | METRIOPHARM AG (CH) | 2017-12-28 | — | — | US | disclosed |
| WO-2017202496-A1 | USE OF 5-AMINO-2,3-DIHYDRO-1,4-PHTHALAZINEDIONE IN THE TREATMENT OF INFLAMMATORY AND/OR DEGENERATIVE DISORDERS OF THE LIGAMENTS OF THE JOINTS, ARTICULAR CAPSULES AND BURSAE | METRIOPHARM AG (CH) | 2017-11-30 | — | — | WO | disclosed |
| EP-3248602-A1 | USE OF 5-AMINO-2,3-DIHYDRO-1,4-PHTHALAZINEDIONE IN THE TREATMENT OF INFLAMMATORY AND/OR DEGENERATIVE DISORDERS OF THE TENDONS, LIGAMENTS OF THE JOINTS, ARTICULAR CAPSULES AND BURSAE | MetrioPharm AG (CH) | 2017-11-29 | — | — | EP | disclosed |
| EP-3233807-A1 | CRYSTALLINE FORM OF 5-AMINO-2,3-DIHYDROPHTHALAZINE-1,4-DIONE SODIUM SALT, PHARMACEUTICAL PREPARATIONS CONTAINING THE SAME AND METHOD FOR THE PRODUCTION OF SAID FORM | MetrioPharm AG (CH) | 2017-10-25 | — | — | EP | disclosed |
| WO-2017140422-A1 | METHOD FOR PRODUCING A CRYSTALLINE FORM OF 5-AMINO-2,3-DIHYDROPHTHALAZINE-1,4-DIONE | METRIOPHARM AG (CH) | 2017-08-24 | — | — | WO | disclosed |
| WO-2017140430-A1 | CRYSTALLINE FORM OF 5-AMINO-2,3-DIHYDROPHTHALAZINE-1,4-DIONE | METRIOPHARM AG (CH) | 2017-08-24 | — | — | WO | disclosed |
| WO-2016096143-A1 | CRYSTALLINE FORM OF 5-AMINO-2,3-DIHYDROPHTHALAZINE-1,4-DIONE SODIUM SALT, PHARMACEUTICAL PREPARATIONS CONTAINING THE SAME AND METHOD FOR THE PRODUCTION OF SAID FORM | METRIOPHARM AG (CH) | 2016-06-23 | — | — | WO | disclosed |
| US-20080171687-A1 | Compositions And Methods For The Preparation And Administration Of Poorly Water Soluble Drugs | ABRAXIS BIOSCIENCE, INC. (US) | 2008-07-17 | — | — | US | disclosed |
| WO-2006034147-A2 | COMPOSITIONS AND METHODS FOR THE PREPARATION AND ADMINISTRATION OF POORLY WATER SOLUBLE DRUGS | ABRAXIS BIOSCIENCE, INC. (US) | 2006-03-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170368063-A1 | CRYSTALLINE FORM OF 5-AMINO-2,3-DIHYDROPHTHALAZINE-1,4-DIONE SODIUM SALT, PHARMACEUTICAL PREPARATIONS CONTAINING THE SAME AND METHOD FOR THE PRODUCTION OF SAID FORM | IL5, DHPS, SCN5A | CHRM4 3593/4885DRD2 716/4885HCRTR2 1715/4885 |
| US-12122753-B2 | Method for solubilizing 5-amino-2,3-dihydro-1,4-phthalazinedione | AASDHPPT, ANXA5, PGA5 | CHRM4 2512/4885DRD2 556/4885HCRTR2 2943/4885 |
| US-20080171687-A1 | Compositions And Methods For The Preparation And Administration Of Poorly Water Soluble Drugs | ABCG2, SI, MLEC | CHRM4 3824/4885DRD2 1120/4885HCRTR2 4800/4885 |
| US-12616695-B2 | Use of 5-amino-2,3-dihydro-1,4-phthalazinedione in the treatment of rare chronic inflammatory pulmonary diseases | CRYZ, PDE12, FKBP5 | CHRM4 904/4885DRD2 3363/4885HCRTR2 2855/4885 |
| US-20250051288-A1 | METHOD FOR SOLUBILIZING 5-AMINO-2,3-DIHYDRO-1,4-PHTHALAZINEDIONE | AASDHPPT, ANXA5, PGA5 | CHRM4 2512/4885DRD2 556/4885HCRTR2 2943/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.